Cost variation analysis of various brands of oral hypolipidemic drugs available in Indian pharmaceutical market
Journal Title: International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP) - Year 2017, Vol 6, Issue 3
Abstract
Introduction Dyslipidemia is the most common risk factor for cardiovascular morbidity and mortality worldwide requiring lifelong therapy. Hence cost of drugs plays an important role in patient’s care necessitating the need for all physicians to keep themselves updated regarding latest prices and price variation of various brands of hypolipidemic drugs. Materials and Methods Cost of oral hypolipidemic drugs manufactured by different pharmaceutical companies in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” (CIMS) April- July 2017. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and percentage variation in cost per 10 tablets was calculated. Results In this study, there exists a wide cost variation among the different brands of same hypolipidemic drug. Percentage cost variation for individual hypolipidemic drugs was found to be highest with atorvastatin (20 mg FC-tablet): 1017.79% followed by rosuvastatin (20mg tablet): 308.16%, gemfibrozil (300mg capsule): 109.14%, lovastatin (20mg tablet): 87.83%, fenofibrate (200mg capsule): 79.53%, simvastatin (5mg tablet): 77.43%, ezetimibe (10mg tablet): 72.84%. Among the fixed dose combination therapy, percentage cost variation was found to be highest with atorvastatin + fenofibrate (10mg + 160mg FC- tablet): 266.67% followed by atorvastatin +ezetimibe (10mg + 10mg tablet): 139.39%, rosuvastatin + fenofibrate (10mg + 160mg tablet): 81.05% Conclusion In Indian market, there exists a wide cost variation amongst various brands of oral hypolipidemic drugs of same strength and dosage forms. Therefore, physicians should be encouraged to prescribe the drugs by generic names as they are cheaper and in no way inferior to costlier branded counterpart. This in turn reduces the economic burden on the patients.
Authors and Affiliations
Mamatha K. R
Keywords
Related Articles
- EP ID EP413182
- DOI -
- Views 93
- Downloads 0
A review of newer therapy in dengue fever
Dengue is a viral disease that at present affects an enormous number of people in over 125 countries and is conscientious for a sizable number of deaths. There is no antiviral chemotherapy or vaccine for dengue virus and...
Phytochemical screening and Polyphenol estimation by HPLC of Terminalia arjuna
Medicinal Plants, as a source of remedies, are widely used as alternative therapeutic tool for the prevention or treatment of many diseases. Our main objective was to evaluate the components in Terminalia arjun samples...
Review on rise of sister disease in type-II Diabetic patients
Current review was regarding the thyroid gland disorder in those patients who are suffering with Type II Diabetes mellitus. Many studies were conducted regarding endocrine disorders. This review highlights the prevalen...
A review on pulmonary diseases
Lung diseases or pulmonary diseases are some of the most common medical conditions in the world. Lung disease affecting airways include asthma, chronic obstructive pulmonary disease. Lung disease affecting the air sacs i...
Cilengitide- A novel therapy in sepsis to prevent antimicrobial resistance
Sepsis is a fast progressing disease, triggered by the host response to infection. If untreated, sepsis can rapidly evolve to multi-organ dysfunction and septic shock. Despite numerous advances in palliative intensive ca...